Breast Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 years or older
- People with breast cancer that has been confirmed by laboratory testing to be HER2-positive (a specific protein found on some cancer cells)
- People with early-stage breast cancer (Stage I, II, or III) that has not spread to distant parts of the body
- People whose treatment plan includes chemotherapy or other systemic therapy before or after surgery, along with local treatment such as surgery and possibly radiotherapy
- People who have signed a written consent form agreeing to take part in the study's specific procedures (there are two levels of consent depending on which part of the study a person is enrolled in)
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose breast cancer has tested HER2-negative
- People with Stage IV (advanced/metastatic) breast cancer that has spread to distant parts of the body
- People who are unable to give informed consent due to capacity issues, or who are unwilling to participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Paola Zagami, Istituto Europeo di Oncologia
Phone: 00390294372437
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Impact of HER2DX on the decision-making processes of the treating physicians and multidisciplinary tumour board, in patients with stage I-III HER2+ BC
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.